Enzalutamide Before Chemotherapy for Prostate Cancer

Although testosterone-suppressive therapy has been the standard of care for initial management of metastatic prostate cancer for more than 7 decades, recent progress in understanding the disease at the molecular level provides compelling evidence that the androgen receptor remains the primary driver of the disease throughout the entire disease course. Next-generation androgen pathway inhibitors such as abiraterone and enzalutamide have received FDA approval by demonstrating survival benefit in patients with advanced prostate cancer following docetaxel chemotherapy.

Now, to test the utility of enzalutamide in metastatic castration-resistant prostate cancer prior to chemotherapy, investigators conducted an industry-sponsored, international, ph…